(Q37837675)

24 August 2017

1 reference

title

Metformin and cancer: new applications for an old drug (English)

1 reference

24 August 2017

1 reference

1

Taxiarchis V Kourelis

1 reference

24 August 2017

Robert D Siegel

2

1 reference

24 August 2017

publication date

8 February 2011

1 reference

24 August 2017

1 reference

24 August 2017

volume

29

1 reference

24 August 2017

issue

2

1 reference

24 August 2017

page(s)

1314-1327

1 reference

Reduction in the Incidence of Type 2 Diabetes with Lifestyle Intervention or Metformin

24 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1007%2FS12032-011-9846-7

Enhancement of the antitumor effect of 1,3-bis(2-chloroethyl)-l-nitrosourea (BCNU) by phenylethylbiguanide (phenformin)

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-011-9846-7

The kinase LKB1 mediates glucose homeostasis in liver and therapeutic effects of metformin

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-011-9846-7

Metformin, independent of AMPK, inhibits mTORC1 in a rag GTPase-dependent manner

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-011-9846-7

On the Origin of Cancer Cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-011-9846-7

TOR, a central controller of cell growth

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-011-9846-7

TSC2 mediates cellular energy response to control cell growth and survival

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-011-9846-7

AMPK phosphorylation of raptor mediates a metabolic checkpoint

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-011-9846-7

AMP-activated protein kinase induces a p53-dependent metabolic checkpoint

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-011-9846-7

Regulation of hypoxia-inducible factor 1alpha expression and function by the mammalian target of rapamycin.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-011-9846-7

mTOR inhibition reverses Akt-dependent prostate intraepithelial neoplasia through regulation of apoptotic and HIF-1-dependent pathways

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-011-9846-7

Effect of metformin on life span and on the development of spontaneous mammary tumors in HER-2/neu transgenic mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-011-9846-7

Metformin is an AMP kinase-dependent growth inhibitor for breast cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-011-9846-7

Metformin inhibits mammalian target of rapamycin-dependent translation initiation in breast cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-011-9846-7

Metformin inhibits breast cancer cell growth, colony formation and induces cell cycle arrest in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-011-9846-7

Metformin induces unique biological and molecular responses in triple negative breast cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-011-9846-7

Differences in risk factors for breast cancer molecular subtypes in a population-based study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-011-9846-7

The antidiabetic drug metformin: a pharmaceutical AMPK activator to overcome breast cancer resistance to HER2 inhibitors while decreasing risk of cardiomyopathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-011-9846-7

Activation of AMPK is necessary for killing cancer cells and sparing cardiac cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-011-9846-7

The antidiabetic drug metformin suppresses HER2 (erbB-2) oncoprotein overexpression via inhibition of the mTOR effector p70S6K1 in human breast carcinoma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-011-9846-7

An intracellular modulation of free radical production could contribute to the beneficial effects of metformin towards oxidative stress

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-011-9846-7

Reactive oxygen species regulate insulin-induced VEGF and HIF-1alpha expression through the activation of p70S6K1 in human prostate cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-011-9846-7

Genome-wide inhibitory impact of the AMPK activator metformin on [kinesins, tubulins, histones, auroras and polo-like kinases] M-phase cell cycle genes in human breast cancer cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-011-9846-7

Dual antiglioma action of metformin: cell cycle arrest and mitochondria-dependent apoptosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-011-9846-7

Prevention of pancreatic cancer induction in hamsters by metformin

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-011-9846-7

The antidiabetic drug metformin exerts an antitumoral effect in vitro and in vivo through a decrease of cyclin D1 level.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-011-9846-7

Systemic treatment with the antidiabetic drug metformin selectively impairs p53-deficient tumor cell growth

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-011-9846-7

Metformin Prevents Tobacco Carcinogen–Induced Lung Tumorigenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-011-9846-7

Diabetes mellitus and breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-011-9846-7

Diabetes mellitus and risk of colorectal cancer: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-011-9846-7

Diabetes mellitus and risk of endometrial cancer: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-011-9846-7

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-011-9846-7

Down-regulation of type I insulin-like growth factor receptor increases sensitivity of breast cancer cells to insulin.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-011-9846-7

Insulin rapidly decreases insulin-like growth factor-binding protein-1 gene transcription in streptozotocin-diabetic rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-011-9846-7

Obesity and cancer risk: the role of the insulin-IGF axis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-011-9846-7

Role of the integrin alphaVbeta3 in mediating increased smooth muscle cell responsiveness to IGF-I in response to hyperglycemic stress

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-011-9846-7

The mammalian unfolded protein response

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-011-9846-7

Chemical Genomics Identifies the Unfolded Protein Response as a Target for Selective Cancer Cell Killing during Glucose Deprivation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-011-9846-7

Enhancing CD8 T-cell memory by modulating fatty acid metabolism

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-011-9846-7

Metformin selectively targets cancer stem cells, and acts together with chemotherapy to block tumor growth and prolong remission

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-011-9846-7

The epithelial-mesenchymal transition generates cells with properties of stem cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-011-9846-7

Metformin against TGFβ-induced epithelial-to-mesenchymal transition (EMT): from cancer stem cells to aging-associated fibrosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-011-9846-7

Metformin inhibits inflammatory angiogenesis in a murine sponge model

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-011-9846-7

Increased cancer-related mortality for patients with type 2 diabetes who use sulfonylureas or insulin

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-011-9846-7

Metformin Suppresses Colorectal Aberrant Crypt Foci in a Short-term Clinical Trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-011-9846-7

Serum insulin, glucose, indices of insulin resistance, and risk of prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-011-9846-7

Insulin, insulin-like growth factor-I, and risk of breast cancer in postmenopausal women

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-011-9846-7

Diabetes mellitus as a risk factor for pancreatic cancer. A meta-analysis

21 January 2018

1 reference

12 December 2020

Type 2 diabetes mellitus and medications for type 2 diabetes mellitus are associated with risk for and mortality from cancer in a German primary care cohort

1 reference

12 December 2020

Metformin decreases angiogenesis via NF-kappaB and Erk1/2/Erk5 pathways by increasing the antiangiogenic thrombospondin-1.

1 reference

12 December 2020

Metformin decreases IGF1-induced cell proliferation and protein synthesis through AMP-activated protein kinase in cultured bovine granulosa cells

1 reference

12 December 2020

Rosiglitazone and risk of cancer: a meta-analysis of randomized clinical trials

1 reference

12 December 2020

Metformin and pathologic complete responses to neoadjuvant chemotherapy in diabetic patients with breast cancer

1 reference

12 December 2020

Diabetes and Cancer: A Consensus Report

1 reference

12 December 2020

Antidiabetic therapies affect risk of pancreatic cancer

1 reference

12 December 2020

Thiazolidinediones and the risk of lung, prostate, and colon cancer in patients with diabetes.

1 reference

12 December 2020

Therapeutic metformin/AMPK activation promotes the angiogenic phenotype in the ERalpha negative MDA-MB-435 breast cancer model

1 reference

12 December 2020

Sulphonylureas and cancer: a case-control study

1 reference

12 December 2020

Experience of malignancies with oral glucose-lowering drugs in the randomised controlled ADOPT (A Diabetes Outcome Progression Trial) and RECORD (Rosiglitazone Evaluated for Cardiovascular Outcomes and Regulation of Glycaemia in Diabetes) clinical t

1 reference

12 December 2020

Methotrexate/nitrous-oxide toxic interaction in perioperative chemotherapy for early breast cancer.

1 reference

12 December 2020

AMP-activated protein kinase activity is critical for hypoxia-inducible factor-1 transcriptional activity and its target gene expression under hypoxic conditions in DU145 cells

1 reference

12 December 2020

Type-II diabetes and pancreatic cancer: a meta-analysis of 36 studies

1 reference

12 December 2020

United Kingdom Prospective Diabetes Study (UKPDS). 13: Relative efficacy of randomly allocated diet, sulphonylurea, insulin, or metformin in patients with newly diagnosed non-insulin dependent diabetes followed for three years

1 reference

12 December 2020

A phase I study of temsirolimus and metformin in advanced solid tumours

1 reference

12 December 2020

[Inhibiting effect of phenformin (phenethyl biguanide) on the growth of Ehrlich carcinoma]

1 reference

12 December 2020

Metformin disrupts crosstalk between G protein-coupled receptor and insulin receptor signaling systems and inhibits pancreatic cancer growth

1 reference

12 December 2020

AMPK in Health and Disease

1 reference

12 December 2020

The combination of metformin and 2-deoxyglucose inhibits autophagy and induces AMPK-dependent apoptosis in prostate cancer cells

1 reference

12 December 2020

Metformin induces apoptosis of pancreatic cancer cells

1 reference

12 December 2020

Metformin inhibits aromatase expression in human breast adipose stromal cells via stimulation of AMP-activated protein kinase

1 reference

12 December 2020

Accumulation of metformin by tissues of the normal and diabetic mouse

1 reference

12 December 2020

Risk of malignancies in patients with diabetes treated with human insulin or insulin analogues: a cohort study

1 reference

12 December 2020

AMPK as a therapeutic target in renal cell carcinoma

1 reference

12 December 2020

Meta-analysis of randomized trials: evaluation of benefit from gemcitabine-based combination chemotherapy applied in advanced pancreatic cancer

1 reference

12 December 2020

Long-term metformin use is associated with decreased risk of breast cancer.

1 reference

12 December 2020

More favorable progesterone receptor phenotype of breast cancer in diabetics treated with metformin

1 reference

12 December 2020

The anti-diabetic drug metformin suppresses self-renewal and proliferation of trastuzumab-resistant tumor-initiating breast cancer stem cells

1 reference

12 December 2020

Dimethylbiguanide inhibits cell respiration via an indirect effect targeted on the respiratory chain complex I.

1 reference

12 December 2020

Important role of the LKB1-AMPK pathway in suppressing tumorigenesis in PTEN-deficient mice

1 reference

12 December 2020

The influence of glucose-lowering therapies on cancer risk in type 2 diabetes

1 reference

12 December 2020

AMP-activated kinase regulates cytoplasmic HuR.

1 reference

12 December 2020

The energy sensing LKB1-AMPK pathway regulates p27(kip1) phosphorylation mediating the decision to enter autophagy or apoptosis

1 reference

12 December 2020

LKB1 and mammalian target of rapamycin as predictive factors for the anticancer efficacy of metformin

1 reference

12 December 2020

Low HDL cholesterol, metformin use, and cancer risk in type 2 diabetes: the Hong Kong Diabetes Registry.

1 reference

12 December 2020

mTOR inhibitors and the anti-diabetic biguanide metformin: new insights into the molecular management of breast cancer resistance to the HER2 tyrosine kinase inhibitor lapatinib (Tykerb).

1 reference

12 December 2020

Cancer risks in thiazolidinedione users compared to other anti-diabetic agents

1 reference

12 December 2020

Association between cancer prevalence and use of thiazolidinediones: results from the Vermont Diabetes Information System

1 reference

12 December 2020

Metabolic immunodepression and metabolic immunotherapy: an attempt of improvement in immunologic response in breast cancer patients by correction of metabolic disturbances

1 reference

12 December 2020

Stimulation of the AMP-activated protein kinase leads to activation of eukaryotic elongation factor 2 kinase and to its phosphorylation at a novel site, serine 398

1 reference

12 December 2020

Insulin glargine use and short-term incidence of malignancies—a population-based follow-up study in Sweden

1 reference

12 December 2020

Metformin and other biguanides in oncology: advancing the research agenda

1 reference

12 December 2020

Metformin in polycystic ovary syndrome

1 reference

12 December 2020

Metformin and reduced risk of cancer in diabetic patients

1 reference

12 December 2020

Metformin regulates breast cancer stem cell ontogeny by transcriptional regulation of the epithelial-mesenchymal transition (EMT) status

1 reference

12 December 2020

Treating the metabolic syndrome.

1 reference

12 December 2020

Metformin, B(12), and enhanced breast cancer response to chemotherapy

1 reference

12 December 2020

Metformin associated with lower cancer mortality in type 2 diabetes: ZODIAC-16

1 reference

12 December 2020

Insulin-like growth factors and cancer

1 reference

12 December 2020

10.1007/S12032-011-9846-7

Identifiers

DOI

1 reference

24 August 2017

1 reference